• Consensus Rating: Hold
  • Consensus Price Target: GBX 315
  • Forecasted Upside: -5.49%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
GBX 333.30
▲ +2.65 (0.80%)

This chart shows the closing price for HLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Haleon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HLN

Analyst Price Target is GBX 315
▼ -5.49% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Haleon in the last 3 months. The average price target is GBX 315, with a high forecast of GBX 376 and a low forecast of GBX 250. The average price target represents a -5.49% upside from the last price of GBX 333.30.

This chart shows the closing price for HLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 contributing investment analysts is to hold stock in Haleon. This rating has held steady since August 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/1/2023JPMorgan Chase & Co.Reiterated RatingUnderweightGBX 250
1/31/2023BarclaysBoost TargetOverweightGBX 360 ➝ GBX 364
1/25/2023Credit Suisse GroupReiterated RatingOutperformGBX 376
12/8/2022Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 300
12/7/2022BarclaysDowngradeOverweightGBX 289 ➝ GBX 360
11/14/2022BarclaysBoost TargetOverweightGBX 850 ➝ GBX 890
11/14/2022Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 300
11/11/2022BarclaysReiterated RatingEqual WeightGBX 298
11/3/2022Credit Suisse GroupLower TargetGBX 368 ➝ GBX 353
10/28/2022Kepler Capital MarketsInitiated CoverageHold$275.00
10/28/2022CheuvreuxInitiated CoverageHoldGBX 275
9/21/2022Royal Bank of CanadaBoost TargetGBX 300 ➝ GBX 320
9/21/2022JPMorgan Chase & Co.Reiterated RatingUnderweightGBX 250
9/21/2022Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 300
9/9/2022Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 300
9/7/2022JPMorgan Chase & Co.Lower TargetUnderweightGBX 280 ➝ GBX 250
8/16/2022Royal Bank of CanadaReiterated RatingSector PerformGBX 300
8/11/2022JPMorgan Chase & Co.Reiterated RatingUnderweightGBX 280
7/21/2022CitigroupReiterated RatingBuyGBX 360
7/19/2022BarclaysUpgradeEqual WeightGBX 348
7/19/2022Credit Suisse GroupReiterated RatingOutperformGBX 368
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/11/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/10/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/10/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
12/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

Haleon logo
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Read More

Today's Range

Now: GBX 333.30
Low: 329.26
High: 336.30

50 Day Range

MA: GBX 317.01
Low: 284.10
High: 333.30

52 Week Range

Now: GBX 333.30
Low: 241.17
High: 337.40

Volume

16,016,910 shs

Average Volume

13,818,499 shs

Market Capitalization

£30.78 billion

P/E Ratio

2,083.13

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Haleon?

The following Wall Street analysts have issued reports on Haleon in the last year: Barclays PLC, Cheuvreux, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Kepler Capital Markets, and Royal Bank of Canada.
View the latest analyst ratings for HLN.

What is the current price target for Haleon?

8 Wall Street analysts have set twelve-month price targets for Haleon in the last year. Their average twelve-month price target is GBX 315, suggesting a possible downside of 5.5%. Credit Suisse Group AG has the highest price target set, predicting HLN will reach GBX 376 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of GBX 250 for Haleon in the next year.
View the latest price targets for HLN.

What is the current consensus analyst rating for Haleon?

Haleon currently has 1 sell rating, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HLN, but not buy more shares or sell existing shares.
View the latest ratings for HLN.

What other companies compete with Haleon?

How do I contact Haleon's investor relations team?

The company's listed phone number is 44 1932 822000. The official website for Haleon is www.haleon.com. Learn More about contacing Haleon investor relations.